企業プロフィール
Aptose Biosciences, Inc. 株価・ニュース・カタリスト
- ティッカー:
- APTO
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Canada and listed in the U
株価変動の要因
Current closing-price context is not available for APTO.
企業概要
Precision Hematology Company
Aptose Biosciences develops small-molecule precision oncology therapies, with an initial focus on acute myeloid leukemia.
Tuspetinib Triplet
The TUSCANY study evaluates tuspetinib with venetoclax and azacitidine as a frontline regimen for newly diagnosed AML patients who are ineligible for intensive induction chemotherapy.
Mutation-Agnostic Strategy
The triplet is intended to provide activity across a genetically diverse AML population without adding overlapping toxicities to the standard venetoclax and azacitidine backbone.
今後のカタリスト
- Updated Phase 1/2 TUSCANY clinical data for the tuspetinib triplet are scheduled for an oral presentation at the June 2026 EHA Congress.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。